Two Cheap, Already-Approved Drugs Stack to Add the Equivalent of ~20 Human Years in Mice

Two Cancer Drugs Combine to Extend Mouse Lifespan by Up to 29%

Researchers at the Max Planck Institute for Biology of Ageing have found that combining two FDA-approved cancer drugs — rapamycin and trametinib — additively extends average lifespan by 29% in female mice and 27% in male mice. Neither drug alone comes close to those numbers. Rapamycin extended lifespan by 17.4% and 16.6% in female and male mice respectively. Trametinib — tested for the first time in this context — added 7.2% and 10.2%. Together, the gains compound.

The mechanism is the point. Rapamycin targets mTOR, a protein regulating cell growth and proliferation. Trametinib targets MEK, a protein in an interconnected pathway. Hit both simultaneously, and the lifespan extensions stack additively rather than overlap. The team also found that combining the drugs lowered tumor prevalence in the liver and spleen — a meaningful secondary finding given both compounds are already used in cancer treatment.

Lead author Linda Partridge was measured about human implications: "We do not expect a similar extension to human lifespans as we found in mice," she said, but added that the drugs could help people "stay healthy and disease-free for longer late in life." Further human research is needed to clarify who might benefit.

Gobble's Take: Two drugs already in oncology clinics may be quietly holding the most credible longevity data in the field — that's not a footnote, that's a lead.

Source: NAD.com

The Soviet-Era Pineal Peptide That Biohackers Are Injecting to Rebuild Telomeres

It started in a Soviet gerontology lab in the 1970s. Researchers at the St. Petersburg Institute of Bioregulation isolated a short peptide chain from the pineal gland — the brain region that governs circadian rhythm and hormonal timing — and called it Epitalon. For decades it sat largely outside Western longevity circles. Now it's one of the most-discussed compounds in biohacking forums, and the reason is specific: animal studies show it can measurably lengthen telomeres, the protective caps on chromosome ends that shorten with every cell division and serve as one of the most reliable biological clocks we have.

The protocol that's circulated isn't casual. Serious users inject 10–20mg subcutaneously over a 10–20 day cycle, twice per year, often stacking it with NAD+ precursors and growth hormone secretagogues like Ipamorelin. The rationale is layered — Epitalon appears to reduce epigenetic noise, stabilize melatonin and cortisol patterns, and upregulate telomerase, the enzyme responsible for telomere maintenance. Small human pilot data and self-reported telomere tests from users have shown measurable lengthening after cycles, though no large randomized trial has confirmed this yet. It is not FDA-approved, and the research base remains thin by clinical standards.

That caveat matters — but so does the mechanism. Telomere length isn't a soft biomarker; it's directly tied to cellular aging and cancer risk.

Gobble's Take: When Soviet gerontologists and Silicon Valley biohackers land on the same molecule independently, it's probably worth understanding before dismissing.

Source: Forj Substack

mTOR: The Most Replicated Longevity Target in Science Still Has Room to Surprise You

Rapamycin has extended lifespan in every major animal model tested — yeast, worms, flies, and mice — making mTOR inhibition one of the most reproducible longevity interventions identified to date. In a landmark 2009 study from the NIA Intervention Testing Program, rapamycin administration starting as late as 20 months of age increased median lifespan in genetically heterogeneous mice by roughly 10–16%. That result has since been replicated across multiple cohorts, strains, and both sexes. The mechanism: inhibiting mTORC1 shifts cells from growth to maintenance mode, boosting autophagy, improving proteostasis, and dialing back cellular senescence — effects that mirror what happens under chronic caloric restriction.

The clinical picture is more complicated. Early human trials hint at improved immune function, cardiovascular markers, and skin health with few side effects. But they also expose real gaps: how to define and measure "aging" as a trial endpoint, how to balance efficacy with safety in healthy people, and how to design studies regulators will accept. Aging isn't recognized as a disease, so trials must target specific age-related conditions. Rapamycin at therapeutic doses can cause immunosuppression, metabolic disruptions, and mouth ulcers. The central dosing challenge is inhibiting mTORC1 enough to slow aging without excessive mTORC2 inhibition, which appears to drive many of the side effects.

Rapalogs like everolimus are already FDA-approved for transplant rejection and certain cancers. The question now is whether lower or intermittent doses can extend healthspan in otherwise healthy older adults.

Gobble's Take: Decades of cross-species replication and FDA-approved drugs already in hand — the bottleneck isn't the science, it's trial design catching up to the biology.

Source: Norngroup Substack

GLP-1 Drugs and AI Clocks Are Reshaping Longevity Research

Between 2023 and 2026, anti-aging research underwent a structural acceleration driven by unprecedented funding, clinical translation of previously theoretical interventions, and AI integration into drug discovery and biomarker development. The Hevolution Foundation committed over $400 million to healthspan science in just 21 months. Altos Labs launched with $3 billion dedicated to cellular reprogramming. The pipeline is no longer theoretical.

Fourteen key domains have reached active investigation simultaneously: senolytics, epigenetic reprogramming, NAD+ metabolism, mTOR inhibition, telomere biology, parabiosis and plasma factors, and more. The PEARL rapamycin trial in healthy humans has been completed. AI-driven aging clocks — now in their fourth generation with causality-enriched designs — can estimate biological age with predictive power surpassing traditional biomarkers. These tools give researchers a precise feedback loop that didn't exist a few years ago.

One of the field's more unexpected developments: GLP-1 receptor agonists, originally developed for diabetes and obesity, have emerged as an entirely new pharmacological avenue in longevity. The first randomized controlled trial evidence now shows GLP-1 agonists reduce epigenetic age. Separately, systemic OSK gene therapy achieved 109% median lifespan extension in aged mice. Critical gaps remain — the TAME metformin trial is still unlaunched, and regulatory frameworks don't yet recognize aging as a treatable condition — but the human data accumulating now dwarfs what existed three years ago.

Gobble's Take: Your biological age is now a number you can actually measure and move — the only question is whether you're paying attention.

Source: ClawRxiv

In Case You Missed It

Yesterday's top stories:

• Your Brain Tells Your Fat to Burn — Via a Hormone Called Irisin
• Precision Longevity Is Here — and It Goes Way Deeper Than Your 23andMe Results
• The Longevity Stack That Doesn't Require a Bryan Johnson Budget